Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galmed PharmaceuticalsGLMD -6.25%29 EV-to-EBIT is 1.24 as of Jul. 14, 2026, which is 29% below its 10-year median of 1.75. GuruFocus rates GLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 371 Biotechnology companies, Galmed Pharmaceuticals ranks better than 75.2% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Galmed Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $-12.22 Mil.
Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galmed Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galmed Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Galmed Pharmaceuticals's EV-to-EBIT falls into.
Galmed Pharmaceuticals's current Enterprise Value is $-11.52 Mil.
Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galmed Pharmaceuticals (GLMD) has a EV-to-EBIT of 1.24 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galmed Pharmaceuticals and its competitors. This is 29% below median its historical median of 1.75. According to the industry distribution chart, Galmed Pharmaceuticals ranks #92 out of 371 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Galmed Pharmaceuticals' EV-to-EBIT too high?
Galmed Pharmaceuticals' current EV-to-EBIT of 1.24 is 29% below median its 10-year median of 1.75. The Biotechnology industry median EV-to-EBIT is 13.76. Galmed Pharmaceuticals' value of 1.24 is 91% below this industry median. Based on the distribution chart, Galmed Pharmaceuticals ranks #92 out of 371 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' EV-to-EBIT compare to FBLG and SXTP?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #92 out of 371 companies for EV-to-EBIT. This places Galmed Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.76. Galmed Pharmaceuticals' value of 1.24 is 91% below this benchmark. While the company's 10-year median is 1.75 vs. the industry median of 13.76, Galmed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.76, based on 371 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galmed Pharmaceuticals's current EV-to-EBIT of 1.24 is 91% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galmed Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galmed Pharmaceuticals's current EV-to-EBIT is 1.24, which is 29% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current EV-to-EBIT of 1.24. The current EV-to-EBIT is 1.24, which is 29% below median its 10-year median of 1.75 and 91% below the Biotechnology industry median of 13.76. Galmed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current EV-to-EBIT is 1.24 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
29GF Score
Get the complete analysis for GLMD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLMD has been successfully added to your 
